Previous work has demonstrated that systemic administration of GM-CSF increases numbers of intraperitoneal MAs, which could be important in ovarian cancer because EOC is primarily a tumor of the peritoneal cavity[12] In our study, the numbers of CXCR3+ MOs increased significantly on day 9 after administration of GM-CSF and rIFN-γ1b (Fig. 3). The gene discussed is CSF2; the disease is ovarian carcinoma.